MiMedx (MDXG) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 17, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'MIMEDX GROUP, INC.	'
Entity Central Index Key	'0001376339	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	105,916,469
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$43,019,559	$44,077,751
Accounts receivable, net	18,966,543	16,092,836
Inventory, net	3,639,094	3,880,776
Prepaid expenses and other current assets	2,278,996	1,337,408
Total current assets	67,904,192	65,388,771
Property and equipment, net of accumulated depreciation	4,288,743	4,086,106
Goodwill	4,040,443	4,040,443
Intangible assets, net of accumulated amortization	11,115,188	11,178,573
Total assets	87,348,566	84,693,893
Current liabilities:	'	'
Accounts payable	2,618,753	2,490,531
Accrued compensation	5,413,595	5,588,811
Accrued expenses	1,369,048	1,405,974
Other current liabilities	192,522	122,551
Total current liabilities	9,593,918	9,607,867
Other liabilities	1,516,464	1,517,956
Total liabilities	11,110,382	11,125,823
Commitments and contingencies (Note 12)	0	0
Stockholders' equity:	'	'
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $.001 par value; 130,000,000 shares authorized; 105,843,137 issued and 105,793,137 outstanding as of March 31, 2014 and 104,425,614 issued and 104,375,614 outstanding as of December 31,2013	105,843	104,426
Additional paid-in capital	150,874,988	147,284,219
Treasury stock (50,000 shares at cost)	-25,000	-25,000
Accumulated deficit	-74,717,647	-73,795,575
Total stockholders' equity	76,238,184	73,568,070
Total liabilities and stockholders' equity	$87,348,566	$84,693,893

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	105,843,137	104,425,614
Common stock, shares outstanding (in shares)	105,793,137	104,375,614
Treasury stock, shares (in shares)	50,000	50,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Net sales	$19,559,188	$11,556,493
Cost of sales	2,977,275	1,905,020
Gross margin	16,581,913	9,651,473
Operating expenses:	'	'
Research and development expenses	1,390,044	1,246,757
Selling, general and administrative expenses	15,851,553	8,369,010
Amortization of intangible assets	231,331	262,596
Operating income (loss)	-891,015	-226,890
Other income (expense), net	'	'
Amortization of debt discount	0	-1,328,439
Interest expense, net	-21,024	-14,804
Income (loss) before income tax provision	-912,039	-1,570,133
Income tax provision	-10,033	-50,275
Net income (loss)	($922,072)	($1,620,408)
Net income (loss) per common share - basic and diluted	($0.01)	($0.02)
Weighted average shares outstanding - basic and diluted	105,358,694	93,128,466

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (USD $)	Total	Convertible Preferred Stock Series A	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Balance at Dec. 31, 2013	$73,568,070	$0	$104,426	$147,284,219	($25,000)	($73,795,575)
Balance (in shares) at Dec. 31, 2013	'	0	104,425,614	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Share-based compensation expense	2,372,364	0	0	2,372,364	0	0
Exercise of stock options	445,072	0	317	444,755	0	0
Exercise of stock options (in shares)	317,193	0	317,193	'	'	'
Exercise of warrants	774,750	0	1,017	773,733	0	0
Exercise of warrants (in shares)	'	0	1,017,000	'	'	'
Issuance of restricted stock	0	0	83	-83	0	0
Issuance of restricted stock (in shares)	'	0	83,330	'	'	'
Net income (loss )	-922,072	0	0	0	0	-922,072
Balance at Mar. 31, 2014	$76,238,184	$0	$105,843	$150,874,988	($25,000)	($74,717,647)
Balance (in shares) at Mar. 31, 2014	'	0	105,843,137	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss )	($922,072)	($1,620,408)
Adjustments to reconcile net income (loss) to net cash from operating activities:	'	'
Depreciation	263,131	98,751
Amortization of intangible assets	231,331	262,596
Amortization of debt discount and deferred financing costs	0	1,328,439
Share-based compensation	2,372,364	984,792
Increase (decrease) in cash resulting from changes in:	'	'
Accounts receivable	-2,873,707	-2,167,942
Inventory	241,682	-933,555
Prepaid expenses and other current assets	-941,588	-555,692
Other assets	0	-249,545
Accounts payable	128,222	-194,977
Accrued compensation	-175,216	765,532
Accrued expenses	-36,926	236,788
Accrued interest	0	-41,641
Other liabilities	101,808	-11,324
Net cash flows from operating activities	-1,610,971	-2,098,186
Cash flows from investing activities:	'	'
Purchases of equipment	-465,768	-73,534
Patent application costs	-167,946	0
Net cash flows from investing activities	-633,714	-73,534
Cash flows from financing activities:	'	'
Proceeds from exercise of warrants	774,750	924,624
Proceeds from exercise of stock options	445,072	232,531
Principal payments of equipment leases	-33,329	-14,813
Net cash flows from financing activities	1,186,493	1,142,342
Net change in cash	-1,058,192	-1,029,378
Cash and cash equivalents, beginning of period	44,077,751	6,754,485
Cash and cash equivalents, end of period	$43,019,559	$5,725,107

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three months ended March 31, 2014 and 2013, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2013, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2013, included in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 4, 2014.
	The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Our biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, and device technology, CollaFix™.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Significant Accounting Policies
	Please see Note 2 to our Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2013, for a description of all significant accounting policies.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $168,000 of patent costs during the first three months of 2014. There were not any patent costs capitalized for the three months ended March 31, 2013.
	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs. For the three months ended March 31, 2014, and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	3 Months Ended
	Mar. 31, 2014
Liquidity and management's plans [Abstract]	'
Liquidity and Management's Plans	'
	Liquidity and Management’s Plans
	As of March 31, 2014, the Company had approximately $43,020,000 of cash and cash equivalents.  The Company reported total current assets of approximately $67,904,000 and current liabilities of approximately $9,594,000 as of March 31, 2014.  The Company believes that its anticipated cash from operating and financing activities, existing cash and cash equivalents, as well as its $3 million line of credit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next twelve months.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consisted of the following items as of March 31, 2014, and December 31, 2013:
		March 31, 2014			December 31, 2013
	Raw materials	$	222,108		$	202,414
	Work in process	2,706,963			2,951,704
	Finished goods	1,033,432			1,048,886
		3,962,503			4,203,004
	Reserve for obsolescence	(323,409		)	(322,228		)
	Inventory, net	$	3,639,094		$	3,880,776

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following as of March 31, 2014, and December 31, 2013:
		March 31,			December 31,
		2014			2013
	Leasehold improvements	$	2,400,837		$	2,319,928
	Lab and clean room equipment	2,632,088			2,025,263
	Furniture and office equipment	1,570,092			1,240,466
	Construction in progress	250,727			802,319
		6,853,744			6,387,976
	Less accumulated depreciation	(2,565,001		)	(2,301,870		)
		$	4,288,743		$	4,086,106
	Included in property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability is included in other liabilities in the accompanying condensed consolidated balance sheets. Interest rates for these leases range from approximately 3% to 12% with maturity dates from September 2016 to January 2018.
	Also included is approximately $1.0 million in leasehold improvements paid for by the landlord of our new facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
	Depreciation expense for the three months ended March 31, 2014 and 2013 was approximately $263,000 and $99,000, respectively.

Intangible_Assets_and_Royalty_

Intangible Assets and Royalty Agreement	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets and Royalty Agreement	'
	Intangible Assets and Royalty Agreement
	Intangible assets are summarized as follows:
				March 31, 2014			December 31, 2013
		Weighted		Cost			Cost
		Average
		Amortization
		Lives
	Licenses (a) (b)	10 years		$	1,009,000		$	1,009,000
	Patents & Know How (b)	14 years		7,855,825			7,798,910
	Customer & Supplier Relationships (b)	14 years		3,761,000			3,761,000
	Tradenames & Trademarks (b)	indefinite		1,008,000			1,008,000
	In Process Research & Development (b)	indefinite		25,000			25,000
	Patents in Process (c)	indefinite		691,018			579,987
	Total			14,349,843			14,181,897
	Less Accumulated amortization and impairment charges			(3,234,655		)	(3,003,324		)
	Net			$	11,115,188		$	11,178,573
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2014, this license had a remaining net book value of approximately $284,000
	(b)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2014 an additional $56,915 of costs associated with patents granted during the period were capitalized and included in Patents & Know- How subject to amortization.
	(c)	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
	Amortization expense for the three months ended March 31, 2014 and 2013 was approximately $231,000, and $263,000, respectively.
	Expected future amortization of intangible assets as of March 31, 2014, is as follows:
	Year ending December 31,	Estimated
		Amortization
		Expense
	2014 (a)	$	695,462
	2015	927,283
	2016	927,283
	2017	837,650
	2018	827,683
	Thereafter	5,891,827
		$	10,107,188
	(a) Estimated amortization expense for the year ending December 31, 2014 includes only amortization to be recorded after March 31, 2014.

Line_of_Credit

Line of Credit	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Line of Credit	'
	Line of Credit
	On May 17, 2013, the Company and Bank of America, N.A. (the “Lender”) entered into a Loan Agreement (the “Loan Agreement”).  The Loan Agreement provides the Company with a secured revolving line of credit (the “Revolving Line of Credit”) of up to $3,000,000, and includes a sub-limit of up to $1,000,000 for the issuance of letters of credit.  The Revolving Line of Credit is secured by the Company's accounts receivable and inventory.  The Company intends to utilize the Revolving Line of Credit for general corporate purposes. As of the date of this filing, the Company has not made any draws under the Revolving Line of Credit.
	Accrued interest with respect to principal amounts outstanding under the Loan Agreement is payable in arrears on a monthly basis calculated at the rate of LIBOR plus two percent (2%). The principal amount outstanding under the Loan Agreement and any accrued and unpaid interest is due no later than May 1, 2014, and the Revolving Line of Credit is subject to certain prepayment penalties upon early termination of the Revolving Line of Credit.   The Loan Agreement is subject to renewal by the Lender at the end of the term.
	The Loan Agreement contains covenants that limit, under certain circumstances, the ability of the Company to, among other things, merge with or acquire other entities, incur new liens, incur additional indebtedness, sell assets outside of the ordinary course of business, make loans, advances or other extensions of credit or engage in any business activities substantially different from the Company's present business without the Lender's consent. The Loan Agreement also requires the Company to maintain certain financial covenants, including a minimum funded debt to adjusted EBITDA ratio and a minimum fixed charge coverage ratio. Management is not aware of any violations of these covenants.

Net_Income_loss_Per_Share

Net Income (loss) Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Income (loss) Per Share	'
	Net Income (loss) Per Share
	Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method.  For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive.
	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended March 31,
		2014				2013
	Net income (loss)	$	(922,072	)		$	(1,620,408	)
	Denominator for basic earnings per share - weighted average shares	105,358,694				93,128,466
	Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—				—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	105,358,694				93,128,466
	Income (loss) per common share - basic and diluted	$	(0.01	)		$	(0.02	)
	(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:
		Three months ended March 31,
		2014			2013
	Outstanding Stock Options	17,142,303			16,022,703
	Outstanding Warrants	267,816			2,344,002
	Restricted Stock Awards	942,084			257,500
		18,352,203			18,624,205

Equity

Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Equity	'
	Equity
	Stock Incentive Plans
	The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at March 31, 2014, totaled 375,000.  On February 25, 2014, the Board of Directors approved 4,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock which can be issued under the 2006 Plan to 26,500,000 at March 31, 2014, subject to the ratification and approval by the Company's stockholders.
	Activity with respect to the stock options is summarized as follows:
		Number		Weighted-				Weighted-Average	Aggregate
		of		Average				Remaining	Intrinsic
		Shares		Exercise				Contractual Term	Value
				Price				(in years)
	Outstanding at January 1, 2014	15,375,960		$	2.46
	Granted	2,094,369		7.29
	Exercised	(317,193	)	1.42
	Unvested options forfeited	(10,833	)	1.24
	Vested options expired	—		—
	Outstanding at March 31, 2014	17,142,303		3.07				7.8	$	55,171,947
	Vested at March 31, 2014	8,777,850		1.69				6.8	38,950,079
	Vested or expected to vest at March 31, 2014 (a)	16,742,166		$	3.01			7.7	$	54,754,819
	(a)	Includes forfeiture adjusted unvested shares.
	The intrinsic value of the options exercised during the three months ended March 31, 2014, was approximately $1,977,000.
	Following is a summary of stock options outstanding and exercisable at March 31, 2014:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-Average		Weighted-			Number Exercisable		Weighted-
				Remaining		Average					Average
				Contractual Term		Exercise					Exercise Price
				(in years)		Price
	$0.50 - $0.76	1,165,935		3.9		$	0.66		1,165,935		$	0.66
	$0.87 - $1.35	6,364,011		7.4		1.2			4,791,313		1.2
	$1.40 - $2.29	1,571,700		5.8		1.64			1,321,698		1.66
	$2.33 - $3.75	2,042,318		8.5		2.75			605,964		2.77
	$3.95 - $5.99	3,263,670		9		5.08			892,940		4.99
	$6.02 - $8.34	2,734,669		9.3		7.09			—		—
		17,142,303		7.8		$	3.07		8,777,850		$	1.69
	Total unrecognized compensation expense related to granted stock options at March 31, 2014, was approximately $18,212,000 and is expected to be recognized over a weighted-average period of 2.4 years.
	The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Three Months Ended March 31,
		2014		2013
	Expected volatility	64.1	%	64.3	%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	1.69% - 1.96%		0.98%-1.86%
	The weighted-average grant date fair value for options granted during the three months ended March 31, 2014 was approximately $4.23.
	Restricted Stock Awards
	Activity with respect to restricted stock awards is summarized as follows.
		Number		Weighted-Average Grant Date
		of		Fair Value
		Shares
	Unvested at December 31, 2013	576,550		$5.53
	Granted	448,864		7.25
	Vested	(83,330	)	5.07
	Forfeited	—		—
	Unvested at March 31, 2014	942,084		$6.39
	As of March 31, 2014, there was approximately $5,440,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.5 years.
	For the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation as follows:
		Three Months Ended March 31,
		2014			2013
	Cost of sales	$	97,516		$	50,162
	Research and development	159,686			75,978
	Selling, general and administrative	2,115,162			858,652
		$	2,372,364		$	984,792
	Warrants
	The Company grants common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long term equity capital to the Company and as additional compensation to consultants and advisors.  The warrants are granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants have been issued for terms of five years.
	Following is a summary of the warrant activity for the three months ended March 31, 2014:
		Number		Weighted-Average
of		Exercise Price
Warrants		per warrant
Warrants outstanding at January 1, 2014	1,284,816		$	0.9
Warrants exercised	(1,017,000	)	0.76
Warrants outstanding at March 31, 2014	267,816		$	1.44
Warrants may be exercised in whole or in part by notice given by the holder accompanied by payment in cash of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased.
These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issuing a variable number of shares.
The warrants require that the Company deliver shares as part of a physical settlement and do not provide for a net-cash settlement.
All of our warrants are classified as equity as of March 31, 2014, and December 31, 2013 and expire at various times through the end of 2016.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income taxes	'
	Income taxes
	The effective tax rates for continuing operations of (1.1%) and (3.2%), respectively, for the three months ended March 31, 2014 and March 31, 2013 were determined using an estimated annual effective tax rate and after considering any discrete items for such periods. Due to a valuation allowance against our U.S. deferred tax assets, the effective tax rate for the three months ended March 31, 2014 does not include the benefit of the current period U.S. tax loss. A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets will be realized.  After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of March 31, 2014. As a result, income tax expense for the three months ended March 31, 2014 is primarily due to income tax expense in certain state jurisdictions.

Supplemental_disclosure_of_cas

Supplemental disclosure of cash flow and non-cash investing and financing activities	3 Months Ended
	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental disclosure of cash flow and non-cash investing and financing activities	'
	Supplemental disclosure of cash flow and non-cash investing and financing activities:
	Selected cash payments, receipts, and noncash activities are as follows:
		Three Months Ended March 31,
		2014		2013
	Cash paid for interest	$	21,024	$	3,688
	Income taxes paid	7,292		7,275
	Purchases of equipment financed through capital leases	—		107,259
	Deferred financing costs	—		27,236
	Stock issuance in connection with Earn-Out Liability of 1,174,915 shares	—		5,792,330
	Stock issuance of 5,272,004 shares in exchange for convertible debt	—		5,272,004

Contractual_Commitments_and_Co

Contractual Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contractual Commitments and Contingencies	'
	Contractual Commitments and Contingencies
	Contractual Commitments
	In addition to the Capital Leases noted above in Note 5, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The estimated annual lease payments are as follows:
	12-month period ended March 31
	2015	$	994,518
	2016	1,309,672
	2017	1,349,400
	2018	1,390,059
	2019	1,192,353
		$	6,236,002
	Rent expense for the three months ended March 31, 2014 and 2013 was approximately $282,000 and $96,000, respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
	Letters of Credit
	As a condition of the leases for the Company's facilities, we are obligated under standby letters of credit in the amount of approximately $525,000. These obligations are reduced at various times over the lives of the leases.
	FDA Untitled Letter and Related Litigation
	Initially, MiMedx processed its tissue allografts in only one form, which was a sheet form. In 2011, MiMedx introduced a micronized form of its sheet allografts.
	The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. If an HCT/P meets the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”), no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required.
	MiMedx believes that all of its tissue products qualify as 361 HCT/Ps. On August 28, 2013, however, the FDA issued an Untitled Letter alleging that the Company’s micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market the micronized products.
	After a series of correspondence and conference calls and a meeting with FDA representatives, in December 2013, the FDA clarified the basis for its position regarding the micronized products. Specifically, the FDA explained its belief that “[c]ryo-milling cut, dehydrated amniotic/chorionic membrane results in a micron-sized powder and the loss of the tensile strength and elasticity that are essential characteristics of the original amniotic/chorionic tissue relating to its utility to function as a ‘physical membrane’ (i.e. covering, barrier).” For this reason, the Agency continues to believe that the micronized products are more than minimally manipulated and the products therefore are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company responded to the FDA that while it does not agree with the Agency’s position, it understands the Agency’s interest in further regulating this emerging technology. Accordingly, the Company has proposed to the FDA that it will pursue the Investigational New Drug (“IND”) and Biologics License Application (“BLA”) process for certain micronized products, and, in parallel, also proposed to enter into negotiations with the FDA on a plan to transition the micronized products to licensed biological products and continue to market the micronized products under specific conditions. The Company had its first Pre-IND meeting at the FDA on March 13, 2014. During the meeting, the Company presented a series of questions focused on detailed plans for its first BLA for its micronized tissue and reviewed some of the Company’s data. The FDA was extremely helpful in answering the Company’s questions and providing additional information related to this complex process. The Company anticipates a second meeting to finalize study protocols and review additional information. There is no guarantee that the FDA will agree to a transition plan or allow us to continue to market our micronized products while we pursue one or more BLAs. If they do allow us to continue to market our micronized products, they may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (“cGMP”). It is also possible that we will be required to recall our micronized products Revenues from micronized products make up about 15% of projected revenues in 2014.
	Following the publication of the Untitled Letter from the FDA regarding the Company’s injectable products in September 2013, the trading price of the Company’s stock dropped sharply and several purported class action lawsuits were filed against us and certain of our executive officers asserting violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s belief that FDA approval was not required to market its products, including its micronized products. These cases have now all been removed to, and consolidated in, the United States District Court for the Northern District of Georgia. By order dated December 9, 2013, the Court approved the appointment of a lead plaintiff and a lead counsel. A Consolidated Amended Class Action Complaint, containing substantially the same causes of action and claims for relief as the initial complaints, was filed on January 27, 2014. On February 26, 2014, the Company filed a Motion to Dismiss on various grounds. The plaintiff filed a Reply Memorandum of Law in opposition to the Company’s Motion to Dismiss on March 28, 2014. On April 14, 2014, the Company filed a Reply Memorandum of Law in further support of its Motion to Dismiss. The Company currently believes that the outcome of this litigation will not have a material adverse impact on our financial position or results of operations.

Subsequent_Events_Notes

Subsequent Events (Notes)	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Line of Credit
	As of May 1, 2014, the Revolving Line of Credit expired and the Company elected not to renew.
	Stock Repurchase Program
	On May 12, 2014, the Company announced that its Board of Directors approved a stock repurchase program. Under the terms of the program, the Company may repurchase up to $10 million of its common stock from time to time through December 31, 2014. The timing and amount of repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	3 Months Ended
	Mar. 31, 2014
Valuation and Qualifying Accounts [Abstract]	'
Schedule II - Valuation and Qualifying Accounts	'
	Schedule II Valuation and Qualifying Accounts
	MIMEDX GROUP, INC. AND SUBSIDIARIES
	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
	Three Months Ended March 31, 2014 and 2013
		Balance at		Additions charged to Expense or Revenue		Deductions			Balance at
		Beginning of Period				and write-offs			End of Period
	For the three months ended March 31, 2014
	Allowance for doubtful accounts	$	407,000	$	125,000	$	(6,000	)	$	526,000
	Allowance for product returns	215,000		201,000		(111,000		)	305,000
	Allowance for obsolescence	322,000		24,000		(23,000		)	323,000
	For the three months ended March 31, 2013
	Allowance for doubtful accounts	49,000		27,000		—			76,000
	Allowance for product returns	89,000		190,000		(167,000		)	112,000
	Allowance for obsolescence	159,000		25,000		—			184,000

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Use of estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
	The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Inventories	'
	Inventories
	Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with operations to maximize recovery of excess inventory.
Revenue Recognition	'
	Revenue Recognition
	The Company sells its products through a combination of a direct sales force and independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with the field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
Patent Costs	'
	Patent Costs
	The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $168,000 of patent costs during the first three months of 2014. There were not any patent costs capitalized for the three months ended March 31, 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The Company considers the applicability and impact of all ASUs. For the three months ended March 31, 2014, and through the date of this report, all ASUs issued, effective and not yet effective, were assessed and determined to be either not applicable or are expected to have minimal impact on our financial position or results of operations.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventories consisted of the following items as of March 31, 2014, and December 31, 2013:
		March 31, 2014			December 31, 2013
	Raw materials	$	222,108		$	202,414
	Work in process	2,706,963			2,951,704
	Finished goods	1,033,432			1,048,886
		3,962,503			4,203,004
	Reserve for obsolescence	(323,409		)	(322,228		)
	Inventory, net	$	3,639,094		$	3,880,776

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment consist of the following as of March 31, 2014, and December 31, 2013:
		March 31,			December 31,
		2014			2013
	Leasehold improvements	$	2,400,837		$	2,319,928
	Lab and clean room equipment	2,632,088			2,025,263
	Furniture and office equipment	1,570,092			1,240,466
	Construction in progress	250,727			802,319
		6,853,744			6,387,976
	Less accumulated depreciation	(2,565,001		)	(2,301,870		)
		$	4,288,743		$	4,086,106

Intangible_Assets_and_Royalty_1

Intangible Assets and Royalty Agreement (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible assets activity summary	'
	Intangible assets are summarized as follows:
				March 31, 2014			December 31, 2013
		Weighted		Cost			Cost
		Average
		Amortization
		Lives
	Licenses (a) (b)	10 years		$	1,009,000		$	1,009,000
	Patents & Know How (b)	14 years		7,855,825			7,798,910
	Customer & Supplier Relationships (b)	14 years		3,761,000			3,761,000
	Tradenames & Trademarks (b)	indefinite		1,008,000			1,008,000
	In Process Research & Development (b)	indefinite		25,000			25,000
	Patents in Process (c)	indefinite		691,018			579,987
	Total			14,349,843			14,181,897
	Less Accumulated amortization and impairment charges			(3,234,655		)	(3,003,324		)
	Net			$	11,115,188		$	11,178,573
	(a)	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2014, this license had a remaining net book value of approximately $284,000
	(b)	On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2014 an additional $56,915 of costs associated with patents granted during the period were capitalized and included in Patents & Know- How subject to amortization.
	(c)	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
Estimated future amortization expense for intangible assets	'
	Expected future amortization of intangible assets as of March 31, 2014, is as follows:
	Year ending December 31,	Estimated
		Amortization
		Expense
	2014 (a)	$	695,462
	2015	927,283
	2016	927,283
	2017	837,650
	2018	827,683
	Thereafter	5,891,827
		$	10,107,188
	(a) Estimated amortization expense for the year ending December 31, 2014 includes only amortization to be recorded after March 31, 2014.

Net_Income_loss_Per_Share_Tabl

Net Income (loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Loss per Share	'
	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended March 31,
		2014				2013
	Net income (loss)	$	(922,072	)		$	(1,620,408	)
	Denominator for basic earnings per share - weighted average shares	105,358,694				93,128,466
	Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	—				—
	Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	105,358,694				93,128,466
	Income (loss) per common share - basic and diluted	$	(0.01	)		$	(0.02	)
	(a) Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:
		Three months ended March 31,
		2014			2013
	Outstanding Stock Options	17,142,303			16,022,703
	Outstanding Warrants	267,816			2,344,002
	Restricted Stock Awards	942,084			257,500
		18,352,203			18,624,205

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stock Options Activity	'
	Activity with respect to the stock options is summarized as follows:
		Number		Weighted-				Weighted-Average	Aggregate
		of		Average				Remaining	Intrinsic
		Shares		Exercise				Contractual Term	Value
				Price				(in years)
	Outstanding at January 1, 2014	15,375,960		$	2.46
	Granted	2,094,369		7.29
	Exercised	(317,193	)	1.42
	Unvested options forfeited	(10,833	)	1.24
	Vested options expired	—		—
	Outstanding at March 31, 2014	17,142,303		3.07				7.8	$	55,171,947
	Vested at March 31, 2014	8,777,850		1.69				6.8	38,950,079
	Vested or expected to vest at March 31, 2014 (a)	16,742,166		$	3.01			7.7	$	54,754,819
	(a)	Includes forfeiture adjusted unvested shares.
Stock Options Outstanding and Exercisable	'
	Following is a summary of stock options outstanding and exercisable at March 31, 2014:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number outstanding		Weighted-Average		Weighted-			Number Exercisable		Weighted-
				Remaining		Average					Average
				Contractual Term		Exercise					Exercise Price
				(in years)		Price
	$0.50 - $0.76	1,165,935		3.9		$	0.66		1,165,935		$	0.66
	$0.87 - $1.35	6,364,011		7.4		1.2			4,791,313		1.2
	$1.40 - $2.29	1,571,700		5.8		1.64			1,321,698		1.66
	$2.33 - $3.75	2,042,318		8.5		2.75			605,964		2.77
	$3.95 - $5.99	3,263,670		9		5.08			892,940		4.99
	$6.02 - $8.34	2,734,669		9.3		7.09			—		—
		17,142,303		7.8		$	3.07		8,777,850		$	1.69
Fair Value of Options, Valuation Assumptions	'
	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
		Three Months Ended March 31,
		2014		2013
	Expected volatility	64.1	%	64.3	%
	Expected life (in years)	6		6
	Expected dividend yield	—		—
	Risk-free interest rate	1.69% - 1.96%		0.98%-1.86%
Restricted Stock Awards Roll Forward	'
	Activity with respect to restricted stock awards is summarized as follows.
		Number		Weighted-Average Grant Date
		of		Fair Value
		Shares
	Unvested at December 31, 2013	576,550		$5.53
	Granted	448,864		7.25
	Vested	(83,330	)	5.07
	Forfeited	—		—
	Unvested at March 31, 2014	942,084		$6.39
Allocation of Share-based Compensation	'
	For the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation as follows:
		Three Months Ended March 31,
		2014			2013
	Cost of sales	$	97,516		$	50,162
	Research and development	159,686			75,978
	Selling, general and administrative	2,115,162			858,652
		$	2,372,364		$	984,792
Summary of Warrants Outstanding	'
	Following is a summary of the warrant activity for the three months ended March 31, 2014:
		Number		Weighted-Average
		of		Exercise Price
		Warrants		per warrant
	Warrants outstanding at January 1, 2014	1,284,816		$	0.9
	Warrants exercised	(1,017,000	)	0.76
	Warrants outstanding at March 31, 2014	267,816		$	1.44

Supplemental_disclosure_of_cas1

Supplemental disclosure of cash flow and non-cash investing and financing activities (Tables)	3 Months Ended
	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities	'
	Selected cash payments, receipts, and noncash activities are as follows:
		Three Months Ended March 31,
		2014		2013
	Cash paid for interest	$	21,024	$	3,688
	Income taxes paid	7,292		7,275
	Purchases of equipment financed through capital leases	—		107,259
	Deferred financing costs	—		27,236
	Stock issuance in connection with Earn-Out Liability of 1,174,915 shares	—		5,792,330
	Stock issuance of 5,272,004 shares in exchange for convertible debt	—		5,272,004

Contractual_Commitments_and_Co1

Contractual Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Estimated Annual Lease, Royalty and Employment Agreement Expenses	'
	In addition to the Capital Leases noted above in Note 5, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The estimated annual lease payments are as follows:
	12-month period ended March 31
	2015	$	994,518
	2016	1,309,672
	2017	1,349,400
	2018	1,390,059
	2019	1,192,353
		$	6,236,002

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2014
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of business segments	1

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (Patents [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, net of accumulated amortization	$168,000	$0

Liquidity_and_Managements_Plan1

Liquidity and Management's Plans (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	17-May-13
					Loan Agreement	Loan Agreement
					Revolving Credit Facility	Revolving Credit Facility
Line of Credit Facility [Line Items]	'	'	'	'	'	'
Cash and cash equivalents	$43,019,559	$44,077,751	$5,725,107	$6,754,485	'	'
Total current assets	67,904,192	65,388,771	'	'	'	'
Total current liabilities	9,593,918	9,607,867	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	'	'	$3,000,000	$3,000,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials	$222,108	$202,414
Work in process	2,706,963	2,951,704
Finished goods	1,033,432	1,048,886
Inventory, gross	3,962,503	4,203,004
Reserve for obsolescence	-323,409	-322,228
Inventory, net	$3,639,094	$3,880,776

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property and equipment [Line Items]	'	'	'
Property and equipment, gross	$6,853,744	'	$6,387,976
Less accumulated depreciation	-2,565,001	'	-2,301,870
Property and equipment, net	4,288,743	'	4,086,106
Capital Leases Interest Rate Effective Percentage Minimum	3.00%	'	'
Capital Leases Interest Rate Effective Percentage Maximum	12.00%	'	'
Depreciation	263,131	98,751	'
Leasehold improvements	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, gross	2,400,837	'	2,319,928
Lab and clean room equipment	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, gross	2,632,088	'	2,025,263
Furniture and office equipment	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, gross	1,570,092	'	1,240,466
Construction in progress	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, gross	250,727	'	802,319
Assets Held under Capital Leases	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, net	427,000	'	'
Leasehold Improvements Paid by Others	'	'	'
Property and equipment [Line Items]	'	'	'
Property and equipment, net	$1,000,000	'	'

Intangible_Assets_and_Royalty_2

Intangible Assets and Royalty Agreement (Details) (USD $)

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jan. 29, 2007

Mar. 31, 2014

Jan. 05, 2011

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jan. 05, 2011

Mar. 31, 2014

Dec. 31, 2013

Jan. 05, 2011

Mar. 31, 2014

Dec. 31, 2013

Jan. 05, 2011

Mar. 31, 2014

Dec. 31, 2013

Jan. 05, 2011

Mar. 31, 2014

Dec. 31, 2013

Licenses

Licenses

Licenses

Licenses

Licenses

Patents & Know How

Patents & Know How

Patents & Know How

Patents & Know How

Customer & Supplier Relationships

Customer & Supplier Relationships

Customer & Supplier Relationships

Tradenames & Trademarks

Tradenames & Trademarks

Tradenames & Trademarks

In Process Research & Development

In Process Research & Development

In Process Research & Development

Patents in Process

Patents in Process

Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Surgical Biologics, LLC

Surgical Biologics, LLC

Surgical Biologics, LLC

Surgical Biologics, LLC

Surgical Biologics, LLC

Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Amortization Lives

'

'

'

'10 years

[1],[2]

'

'

'

'

'14 years

[1]

'

'

'

'14 years

[1]

'

'

'

'

'

'

'

'

'

'

Gross Carrying Value

'

'

'

$1,009,000

[1],[2]

$1,009,000

[1],[2]

'

'

$13,000

$7,855,825

[1]

$7,798,910

[1]

'

$7,690,000

$3,761,000

[1]

$3,761,000

[1]

$3,761,000

'

'

'

'

'

'

'

'

Weighted Average Amortization Lives, Indefinite Lived

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'indefinite

[1]

'

'

'indefinite

[1]

'

'

'indefinite

[3]

'

Gross Carrying Value, Indefinite Lived

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,008,000

[1]

1,008,000

[1]

1,008,000

25,000

[1]

25,000

[1]

25,000

691,018

[3]

579,987

[3]

Total

14,349,843

'

14,181,897

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less Accumulated amortization and impairment charges

-3,234,655

'

-3,003,324

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net

11,115,188

'

11,178,573

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition price

'

'

'

'

'

996,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum time of approval

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payments to licensor

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent royalty to be paid to licensor (in hundredths)

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual royalty payment

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net book value

10,107,188

'

'

'

'

'

284,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Costs

'

'

'

'

'

'

'

'

'

'

56,915

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangible assets

231,331

262,596

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated future amortization expense [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

695,462

[4]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

927,283

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

927,283

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

837,650

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

827,683

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

5,891,827

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net book value

$10,107,188

'

'

'

'

'

$284,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2014 an additional $56,915 of costs associated with patents granted during the period were capitalized and included in Patents & Know- How subject to amortization.

[2]

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2014, this license had a remaining net book value of approximately $284,000

[3]

Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

[4]

Estimated amortization expense for the year ending December 31, 2014 includes only amortization to be recorded after March 31, 2014.

Line_of_Credit_Details

Line of Credit (Details) (Loan Agreement, USD $)	Mar. 31, 2014	17-May-13
Revolving Credit Facility	'	'
Debt Instrument [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$3,000,000	$3,000,000
Letter of Credit	'	'
Debt Instrument [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$1,000,000
London Interbank Offered Rate (LIBOR)	'	'
Debt Instrument [Line Items]	'	'
Annual interest rate (in hundredths)	'	2.00%

Net_Income_loss_Per_Share_Deta

Net Income (loss) Per Share (Details) (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Computation of basic and diluted net loss per share [Abstract]	'		'
Net income (loss )	($922,072)		($1,620,408)
Denominator for basic earnings per share - weighted average shares	105,358,694		93,128,466
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)	0	[1]	0	[1]
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	105,358,694		93,128,466
Income (loss) per common share - basic and diluted (in dollars per share)	($0.01)		($0.02)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	18,352,203		18,624,205
Outstanding Stock Options	'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	17,142,303		16,022,703
Outstanding Warrants	'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	267,816		2,344,002
Restricted Stock Awards	'		'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'
Antidilutive securities excluded from computation of earnings per share (in shares)	942,084		257,500
[1]	Securities outstanding that were excluded from the computation, prior to the use of the treasury stock method, because they would have been anti-dilutive are as follows:B Three months ended March 31,B 2014B 2013Outstanding Stock Options17,142,303B 16,022,703Outstanding Warrants267,816B 2,344,002Restricted Stock Awards942,084B 257,500B 18,352,203B 18,624,205

Equity_Details

Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
	Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'
Number of share-based compensation plans	3		'
Outstanding assumed options (in shares)	375,000		'
Additional shares authorized by Board of Directors (in shares)	4,000,000		'
Shares authorized (in shares)	26,500,000		'
Total unrecognized compensation expense	$18,212,000		'
Number of shares [Roll forward]	'		'
Outstanding, beginning of period (in shares)	15,375,960		'
Granted (in shares)	2,094,369		'
Exercised (in shares)	-317,193		'
Unvested options forfeited (in shares)	-10,833		'
Vested options expired (in shares)	0		'
Outstanding, end of period (in shares)	17,142,303		'
Vested at end of period (in shares)	8,777,850		'
Exercisable options, vested and expected to vest (in shares)	16,742,166	[1]	'
Weighted-Average Exercise Price [Roll forward]	'		'
Outstanding, weighted average exercise price, beginning of period (in dollars per share)	$2.46		'
Granted, weighted average exercise price (in dollars per share)	$7.29		'
Exercised, weighted average exercise price (in dollars per share)	$1.42		'
Unvested options forfeited weighted-average exercise price (in dollars per share)	$1.24		'
Vested options expired weighted-average exercise price (in dollars per share)	$0		'
Outstanding, weighted average exercise price, end of period (in dollars per share)	$3.07		'
Vested at end of period weighted average exercise price (in dollars per share)	$1.69		'
Vested and expected to vest, weighted average exercise price (in dollars per share)	$3.01	[1]	'
Stock options, additional disclosures [Abstract]	'		'
Vested at end of period weighted average remaining contractual term	'6 years 9 months 18 days		'
Vested and expected to vest, weighted average remaining contractual term	'7 years 8 months 12 days	[1]	'
Outstanding intrinsic value	55,171,947		'
Vested at end of period aggregate intrinsic value	38,950,079		'
Vested and expected to vest, aggregate intrinsic value	54,754,819	[1]	'
Exercised options, intrinsic value	1,977,000		'
Number of outstanding options (in shares)	17,142,303		'
Outstanding Options, weighted average remaining contractual term	'7 years 9 months 18 days		'
Outstanding Options, weighted average exercise price (in dollars per share)	$3.07		'
Number of exercisable options (in shares)	8,777,850		'
Exercisable Options, weighted average exercise price (in dollars per share)	$1.69		'
Fair value options valuation assumptions [Abstract]	'		'
Expected volatility	64.10%		64.30%
Expected life (in years)	'6 years		'6 years
Expected dividend yield	0.00%		0.00%
Risk-free interest rate, minimum (in hundredths)	1.69%		0.98%
Risk-free interest rate, maximum (in hundredths)	1.96%		1.86%
Share-based Compensation [Abstract]	'		'
Share-based compensation expense	2,372,364		984,792
Weighted-average grant date fair value for options granted during the period (in dollars per share)	$4.23		'
Warrants, term	'5 years		'
Warrants	'		'
Warrants, Number of Warrants [Roll Forward]	'		'
Warrants outstanding, beginning of period (in shares)	1,284,816		'
Warrants exercised (in shares)	-1,017,000		'
Warrants outstanding, end of period (in shares)	267,816		'
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]	'		'
Warrants outstanding, beginning of period (in dollars per share)	0.9		'
Warrants exercised (in dollars per share)	0.76		'
Warrants outstanding, end of period (in dollars per share)	1.44		'
Cost of Products Sold	'		'
Share-based Compensation [Abstract]	'		'
Share-based compensation expense	97,516		50,162
Research and Development	'		'
Share-based Compensation [Abstract]	'		'
Share-based compensation expense	159,686		75,978
Selling, General and Administrative	'		'
Share-based Compensation [Abstract]	'		'
Share-based compensation expense	2,115,162		858,652
$0.50 - $0.76	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$0.50		'
Exercise Price Range, upper range limit (in dollars per share)	$0.76		'
Number of outstanding options (in shares)	1,165,935		'
Outstanding Options, weighted average remaining contractual term	'3 years 10 months 24 days		'
Outstanding Options, weighted average exercise price (in dollars per share)	$0.66		'
Number of exercisable options (in shares)	1,165,935		'
Exercisable Options, weighted average exercise price (in dollars per share)	$0.66		'
$0.87 - $1.35	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$0.87		'
Exercise Price Range, upper range limit (in dollars per share)	$1.35		'
Number of outstanding options (in shares)	6,364,011		'
Outstanding Options, weighted average remaining contractual term	'7 years 4 months 24 days		'
Outstanding Options, weighted average exercise price (in dollars per share)	$1.20		'
Number of exercisable options (in shares)	4,791,313		'
Exercisable Options, weighted average exercise price (in dollars per share)	$1.20		'
$1.40 - $2.29	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$1.40		'
Exercise Price Range, upper range limit (in dollars per share)	$2.29		'
Number of outstanding options (in shares)	1,571,700		'
Outstanding Options, weighted average remaining contractual term	'5 years 9 months 18 days		'
Outstanding Options, weighted average exercise price (in dollars per share)	$1.64		'
Number of exercisable options (in shares)	1,321,698		'
Exercisable Options, weighted average exercise price (in dollars per share)	$1.66		'
$2.33 - $3.75	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$2.33		'
Exercise Price Range, upper range limit (in dollars per share)	$3.75		'
Number of outstanding options (in shares)	2,042,318		'
Outstanding Options, weighted average remaining contractual term	'8 years 6 months		'
Outstanding Options, weighted average exercise price (in dollars per share)	$2.75		'
Number of exercisable options (in shares)	605,964		'
Exercisable Options, weighted average exercise price (in dollars per share)	$2.77		'
$3.95 - $5.99	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$3.95		'
Exercise Price Range, upper range limit (in dollars per share)	$5.99		'
Number of outstanding options (in shares)	3,263,670		'
Outstanding Options, weighted average remaining contractual term	'9 years		'
Outstanding Options, weighted average exercise price (in dollars per share)	$5.08		'
Number of exercisable options (in shares)	892,940		'
Exercisable Options, weighted average exercise price (in dollars per share)	$4.99		'
$6.02 - $8.34	'		'
Stock options, additional disclosures [Abstract]	'		'
Exercise Price Range, lower range limit (in dollars per share)	$6.02		'
Exercise Price Range, upper range limit (in dollars per share)	$8.34		'
Number of outstanding options (in shares)	2,734,669		'
Outstanding Options, weighted average remaining contractual term	'9 years 3 months 18 days		'
Outstanding Options, weighted average exercise price (in dollars per share)	$7.09		'
Number of exercisable options (in shares)	0		'
Exercisable Options, weighted average exercise price (in dollars per share)	$0		'
Stock Options	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'
Expenses expected to be recognized over a weighted-average period	'2 years 4 months 24 days		'
Restricted Stock Awards	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'
Expenses expected to be recognized over a weighted-average period	'2 years 6 months		'
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$5,440,000		'
Number of Shares	'		'
Beginning Balance	576,550		'
Granted	448,864		'
Vested	-83,330		'
Forfeited	0		'
Ending Balance	942,084		'
Weighted- Average Grant Date Fair Value	'		'
Beginning Balance (in dollars per share)	$5.53		'
Granted (in dollars per share)	$7.25		'
Vested (in dollars per share)	$5.07		'
Forfeited (in dollars per share)	$0		'
Beginning Balance (in dollars per share)	$6.39		'
[1]	Includes forfeiture adjusted unvested shares.

Income_taxes_Details

Income taxes (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Effective tax rate (as a percentage)	1.10%	3.20%

Supplemental_disclosure_of_cas2

Supplemental disclosure of cash flow and non-cash investing and financing activities (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]	'	'
Cash paid for interest	$21,024	$3,688
Income taxes paid	7,292	7,275
Purchases of equipment financed through capital leases	0	107,259
Deferred financing costs	0	27,236
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares	0	5,792,330
Stock issued for earn-out liability (in shares)	0	1,174,915
Stock issuance of 5,272,004 shares in exchange for convertible debt	$0	$5,272,004
Stock issued for convertible debt (in shares)	0	5,272,004

Contractual_Commitments_and_Co2

Contractual Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Loss Contingencies [Line Items]	'	'
Rent expense	$282,000	$96,000
Estimated annual lease, royalty, and employment agreement expenses [Abstract]	'	'
2015	994,518	'
2016	1,309,672	'
2017	1,349,400	'
2018	1,390,059	'
2019	1,192,353	'
Total Contractual commitments	6,236,002	'
Standby Letters of Credit	'	'
Loss Contingencies [Line Items]	'	'
Standby letters of credit	$525,000	'

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event, USD $)	8 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Subsequent Event	'
Subsequent Event [Line Items]	'
Authorized share amount for repurchase	$10

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Allowance for doubtful accounts	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'
Balance at Beginning of Period	$407,000	$49,000
Additions charged to Expense or Revenue	125,000	27,000
Deductions and write-offs	-6,000	0
Balance at End of Period	526,000	76,000
Allowance for product returns	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'
Balance at Beginning of Period	215,000	89,000
Additions charged to Expense or Revenue	201,000	190,000
Deductions and write-offs	-111,000	-167,000
Balance at End of Period	305,000	112,000
Allowance for obsolescence	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'
Balance at Beginning of Period	322,000	159,000
Additions charged to Expense or Revenue	24,000	25,000
Deductions and write-offs	-23,000	0
Balance at End of Period	$323,000	$184,000